| 2020-ZHOU-68954 | |
| Intravenous and oral antibiotics are not always effective for lung infections due to limited drug exposure at the infection site and bacterial resistance. Researchers at Purdue University have developed a novel combination therapy of polymyxins for treating bacterial lung infections. Polymyxins have often been used as the last-line resort for infections caused by multi-drug resistant Gram-negative ‘superbugs’; but Inhaled polymyxins can cause toxicity in the lungs. The novel formulation developed by Purdue researchers creates a powerful therapeutic option with better antibacterial killing and much-reduced toxicity than the polymyxins alone. The Purdue dry powder formulation shows promise as an inhaled therapy, with satisfactory stability and high aerosolization performance. This innovative inhalation formulation promises a life-saving option for patients suffering from bacterial lung infections, including people infected by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales. Advantages: -Enhanced efficacy -Decreased drug resistance -Decreased toxicity Potential Applications: -Pharmaceuticals -Biomedical -Medicine Related Publication: Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance Mol. Pharmaceutics, Published online July 24, 2020 https://doi.org/10.1021/acs.molpharmaceut.0c00390 |
|
|
|
|
Mar 5, 2021
PCT-Patent
WO
(None)
(None)
Mar 11, 2020
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |